Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bumetanide

FDA-approved product (tablet, oral), marketed as Bumetanide, Bumex, Enbumyst.

Registered studies
49
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Bumetanide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Kidney disease
  • Nephrotic syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Loop Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bumetanide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bumetanide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial

    NCT05129722 · start 2022-10-01

    Registered record
    Registry ID
    NCT05129722
    Conditions
    Heart Failure With Preserved Ejection Fraction
    Interventions
    Low dose combination polydiuretic therapy; Comparator monotherapy empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-10-01
    Completion
    2024-05-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Preserved Ejection Fraction
    InterventionLow dose combination polydiuretic therapy; Comparator monotherapy empagliflozin
    PhasePhase 4
    Registry statusTerminated

  • Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment

    NCT05411991 · start 2022-06-12

    Registered record
    Registry ID
    NCT05411991
    Conditions
    Acute Heart Failure; Diuretics Drug Reactions
    Interventions
    UNa measurement after intravenous loop diuretic bolus; Intravenous acetazolamide 500 mg OD; Intravenous bumetanide TID; Oral chlorthalidone OD; Intravenous canrenoate 200 mg OD; Maintenance infusion; Oral potassium supplements; Intravenous hypertonic saline; Switch to oral diuretic therapy; Usual AHF care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-06-12
    Completion
    2024-07-01
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Heart Failure; Diuretics Drug Reactions
    InterventionUNa measurement after intravenous loop diuretic bolus; Intravenous acetazolamide 500 mg OD; Intravenous bumetanide TID; Oral chlorthalidone OD +6 more
    PhasePhase 4
    Registry statusCompleted

  • Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

    NCT05323487 · start 2022-06-01

    Registered record
    Registry ID
    NCT05323487
    Conditions
    Heart Failure
    Interventions
    Bumetanide Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-06-01
    Completion
    2027-05-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionBumetanide Injection
    PhasePhase 1
    Registry statusRecruiting

  • Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

    NCT06218199 · start 2021-07-08

    Registered record
    Registry ID
    NCT06218199
    Conditions
    Heart Failure, Congestive
    Interventions
    Furosemide; Torsemide; Bumetanide; sacubitril/valsartan; Hydralazine; Isosorbide Dinitrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2021-07-08
    Completion
    2026-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure, Congestive
    InterventionFurosemide; Torsemide; Bumetanide; sacubitril/valsartan +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure

    NCT04572867 · start 2021-06-08

    Registered record
    Registry ID
    NCT04572867
    Conditions
    Heart Failure; Congestive Heart Failure; Decompensated Heart Failure
    Interventions
    Aquapheresis; IV Diuretics
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2021-06-08
    Completion
    2021-07-27
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Congestive Heart Failure; Decompensated Heart Failure
    InterventionAquapheresis; IV Diuretics
    PhaseNot applicable
    Registry statusWithdrawn

  • Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus

    NCT04697485 · start 2021-01-08

    Registered record
    Registry ID
    NCT04697485
    Conditions
    HF - Heart Failure; Diabetes Mellitus
    Interventions
    Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-01-08
    Completion
    2022-03-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHF - Heart Failure; Diabetes Mellitus
    InterventionBumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
    PhasePhase 4
    Registry statusWithdrawn

  • Role of Bumetanide in Treatment of Autism

    NCT04766177 · start 2021-01-01

    Registered record
    Registry ID
    NCT04766177
    Conditions
    Autism
    Interventions
    Bumetanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-01-01
    Completion
    2030-12-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism
    InterventionBumetanide; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD

    NCT04192110 · start 2020-08-11

    Registered record
    Registry ID
    NCT04192110
    Conditions
    Chronic Kidney Disease
    Interventions
    Diuretic initiation or augmentation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2020-08-11
    Completion
    2020-08-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionDiuretic initiation or augmentation
    PhasePhase 4
    Registry statusWithdrawn

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

    NCT03923933 · start 2019-06-18

    Registered record
    Registry ID
    NCT03923933
    Conditions
    Renal Insufficiency, Chronic
    Interventions
    Chlorthalidone; Bumetanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-06-18
    Completion
    2019-10-28
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency, Chronic
    InterventionChlorthalidone; Bumetanide
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease

    NCT03899324 · start 2019-04-26

    Registered record
    Registry ID
    NCT03899324
    Conditions
    Parkinson Disease
    Interventions
    Bumetanide white, oblong, scored tablet; Placebo white, oblong, scored tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-04-26
    Completion
    2021-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBumetanide white, oblong, scored tablet; Placebo white, oblong, scored tablet
    PhasePhase 2
    Registry statusUnknown

  • Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure

    NCT03709160 · start 2018-10-15

    Registered record
    Registry ID
    NCT03709160
    Conditions
    Heart Failure; Congestive Heart Failure
    Interventions
    Bumetanide 1 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-10-15
    Completion
    2019-10-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Congestive Heart Failure
    InterventionBumetanide 1 MG
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

    NCT03715153 · start 2018-10-04

    Registered record
    Registry ID
    NCT03715153
    Conditions
    Autism Spectrum Disorder (ASD)
    Interventions
    BUMETANIDE (S95008) for week 0 - 26; PLACEBO for week 0 - 26; Open-Label BUMETANIDE (S95008) for weeks 26 - 52
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-10-04
    Completion
    2021-10-26
    Enrolment
    211

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder (ASD)
    InterventionBUMETANIDE (S95008) for week 0 - 26; PLACEBO for week 0 - 26; Open-Label BUMETANIDE (S95008) for weeks 26 - 52
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

    NCT03715166 · start 2018-09-24

    Registered record
    Registry ID
    NCT03715166
    Conditions
    Autism Spectrum Disorder (ASD)
    Interventions
    Bumetanide Oral Solution; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-09-24
    Completion
    2021-09-13
    Enrolment
    211

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder (ASD)
    InterventionBumetanide Oral Solution; Placebo
    PhasePhase 3
    Registry statusTerminated